Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

Not Applicable

Recruiting

Interventions: Other: Enhanced reminders
Other: Standard CANImmunize notifications

Brief Summary: The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are:

* Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users?

* What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users?

Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.

Recruitment & Eligibility

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Arm && Interventions

Group	Intervention	Description
Enhanced reminders	Enhanced reminders	-
Standard notifications	Standard CANImmunize notifications	-

Primary Outcome Measures

Name	Time	Method
Receipt of 12-month pneumococcal vaccine	12 months of age	Receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record

Secondary Outcome Measures

Name	Time	Method
Timeliness of 12-month pneumococcal vaccine	12-13 months of age will be considered as timely, after 13 months considered late	Age at receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial